Searchable abstracts of presentations at key conferences in endocrinology

ea0032p23 | Adrenal cortex | ECE2013

Immunohistochemical markers of adrenal cortical tumors

Altieri Barbara , Fadda Guido , Capozzi Anna , Pontecorvi Alfredo , Casa Silvia Della

Introduction: Adrenocortical tumors (ACTs) are usually divided in adenoma (ACA) or carcinoma (ACC) according to histopathologic methods. Some lesions are occasionally difficult to classify according to these criteria. We studied the use of some immunohistochemical markers to recognise the difference between malignant and benign tumors.Materials and methods: We studied 12 patients affected by ACC and 10 by ACA. Clinical evaluation and hormone analysis wer...

ea0075m03 | Metabolic Bone | EYES2021

Management of a rare life-threatening parathyroid carcinoma

Zelano Lorenzo , Maggio Ettore , Veleno Miriam , Mura Chiara , Morgante Cesare , Antonio Rota Carlo , Pontecorvi Alfredo

Background: Parathyroid carcinoma (PC) is rare, usually presenting with hyperparathyroidism and severe hypercalcemia. A standardized diagnostic, prognostic and therapeutic approach has not been provided yet and TNM staging algorithm is not universally accepted. Surgery is the first-choice treatment and is the only effective therapy to control hypercalcaemia. Chemo- or radio-therapy, local treatments or novel drugs should be reserved to selected cases.Cas...

ea0075t11 | Thyroid | EYES2021

Safety profile of Lenvatinib treatment in a mildly symptomatic Covid19 patient

Menotti Sara , Mura Chiara , Corsello Andrea , Ramunno Vittoria , Raia Salvatore , Maria Rosa , Pontecorvi Alfredo

Background: Lenvatinib is an oral chemotherapy for metastatic radioiodine-refractory differentiated thyroid cancer (RRDTC) which significantly improves progression free survival (PFS). It has been proved that higher rates of dose interruption or reduction of Lenvatinib have a negative impact on PFS. Patients with active cancer, such as RRDTC, have an increased risk of contracting Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) and developing complications, especial...

ea0099p94 | Endocrine-Related Cancer | ECE2024

Cervico-mediastinal hematoma: Atypical presentation of parathyroid carcinoma associated to hashimoto thyroiditis

Cicia Martina , Papi Giampaolo , Scillitani Alfredo , Corrado Stefania , Locantore Pietro , Pontecorvi Alfredo

Introduction: Parathyroid carcinoma (PC) accounts for <1% of all forms of primary hyperparathyroidism. PC is characterized by very high serum PTH and calcium levels and presents with osteopenia/osteoporosis, nephrolithiasis, asthenia, neuropsychiatric symptoms. Here, we report the unusual presentation of a PC.Case presentation: A 48-year-old woman was referred to our Center for the sudden appearance of a large painful hematoma in the cervico-mediasti...

ea0049oc12.5 | Pituitary Clinical | ECE2017

Effects of pegvisomant and somatostatin receptor ligands on risk of vertebral fractures in patients with Acromegaly

Chiloiro Sabrina , Mazziotti Gherardo , Giampietro Antonella , Formenti Anna Maria , Bianchi Antonio , Mormando Marilda , Pontecorvi Alfredo , Giustina Andrea , De Marinis Laura

Acromegalic osteopathy is an emerging complication of chronic GH excess characterized by increase in bone turnover, deterioration in bone microarchitecture and high risk of vertebral fractures (VFs). Medical therapies may exert direct effects on peripheral targets leading to improvement of clinical outcomes regardless of biochemical control of acromegaly. In this longitudinal study, we compared the effects pegvisomant (PegV) and somatostatin receptor ligands (SRLs) on VF risk ...

ea0049ep1341 | Thyroid (non-cancer) | ECE2017

Is Levothyroxine requirement the same for tablet and soft gel formulation in postsurgical hypothyroidism?

Di Donna Vincenzo , Paragliola Rosa Maria , De Waure Chiara , De Rosa Annapina , Papi Giampaolo , Pontecorvi Alfredo , Corsello Salvatore Maria

Background: In a previous publication we identified the major predictive factors of levothyroxine (LT4) requirement and proposed an efficient nomogram to calculate LT4 substitutive starting dose after total thyroidectomy for benign disease. The aim of this study was to assess whether the LT4 requirement differs between the tablet and the soft gel capsules formulations.Methods: One hundred and three consecutive patients su...

ea0041gp238 | Thyroid Cancer (1) | ECE2016

Correlation between basal and stimulated thyroglobulin in differentiated thyroid carcinoma of intermediate and high risk

Senes Paola , De Rosa Annapina , Paragliola Rosa Maria , Papi Giampaolo , Locantore Pietro , Pontecorvi Alfredo , Corsello Salvatore Maria

Thyroglobulin (Tg) is a highly sensitive tumor marker of differentiated thyroid cancer (DTC). To optimize the sensitivity, guidelines recommend Tg measurement after stimulation with recombinant TSH (rh-TSH) 6–12 months after radio remnant ablation (RRA). Based on recent evidence in Literature, it is possible to avoid the measurement of Tg after stimulation with rh-TSH (S-Tg) in presence of undetectable values of basal Tg (B-Tg) if high functional sensitivity (0.1 ng/ml) m...

ea0035p1140 | Thyroid Cancer | ECE2014

Thyroglobulin before radio remnant ablation during levothyroxine withdrawal can be considered an accurate parameter of remission of differentiated thyroid cancer

Paragliola Rosa Maria , De Rosa Annapina , Di Donna Vincenzo , Locantore Pietro , Senes Paola , Prete Alessandro , Pontecorvi Alfredo , Corsello Salvatore Maria

Introduction: Differentiated thyroid cancer (DTC) is the most frequent endocrine cancer. After surgery followed, if any, by 131I radio remnant ablation (RRA), follow-up monitoring consists of neck ultrasonography (US) and measurements of thyroglobulin (Tg) levels and anti-Tg antibodies (Ac-Tg) both on levothyroxine (L-T4) therapy and after recombinant TSH (rTSH). The aim of our study is to define a cut-off of Tg before RRA (RRA-Tg) during <...

ea0070aep608 | Pituitary and Neuroendocrinology | ECE2020

Metabolism of glucose in patients with acromegaly treated with Pegvisomant and/or Pasireotide LAR after resistance to first generation somatostatin receptor ligands

Chiloiro Sabrina , Giampietro Antonella , Bianchi Antonio , Maria Formenti Anna , Maya Fleseriu Cara , Pontecorvi Alfredo , Giustina Andrea , De Marinis Laura

Introduction: Acromegaly (Acro) is characterized by insulin sensitivityreduction, glucose intolerance (IGT) and diabetes mellitus (DM2 in 15%–38% of patients). Studies that investigated action of medical therapies for acro on glucose metabolism, didn’t provide conclusive data. Association between blood glucose (BG) levels and serum IGF-I levels in patients with DM2 and acro has been suggested, however,IGF-I levels and hemoglobin A1c (HbA1c) correlation is still con...

ea0070ep461 | Thyroid | ECE2020

Immunoassay interference on thyroid functions tests during treatment with Nivolumab

Maria Paragliola Rosa , Corsello Andrea , Papi Giampaolo , Melfa Eleonora , Urbani Andrea , Pontecorvi Alfredo , Carrozza Cinzia , Maria Corsello Salvatore

Background: Immune checkpoint inhibitors (ICI), anticancer therapy blocking specific molecules expressed in tumor microenvironment, are associated to several endocrine side effects. In particular, the use of PD-1/PD-L1 inhibitors is related to a higher incidence of thyroid dysfunction. The most frequent form of thyrotoxicosis is a destructive thyroiditis, which can evolve into hypothyroidism.Patient findings:We report the case of an 85 years-old patient,...